CEO Willsey led a cluster of 3 unique insiders buying ~$385K at $4.75, one insider adding a 196% ownership increase — real conviction, not noise. Setup is a capitulation buy: RSI 27, 26% off the 52w high after a pullback, sitting right at the insider price, with clean net flow and no selling. Catalyst support from Q2 continuing-ops revenue up 39% to $13.2M and gross margin improving to 55.6%; target is a reclaim of the MA20 near $5.85 (+23% room), with the prior $6.40 high above that.
Watch: Micro-cap ($178M) healthcare name, unprofitable with debt ($40M) above cash ($22M) and negative FCF; single-source signal and earnings ~80 days out (no near-term blackout tell).